McClelland R A, Berger U, Wilson P, Powles T J, Trott P A, Easton D, Gazet J C, Coombes R C
Ludwig Institute for Cancer Research (London-St. George's Group), Tooting, London, United Kingdom.
Cancer Res. 1987 Nov 15;47(22):6118-22.
We have developed an immunocytochemical staining procedure (ERICA) using a monoclonal antibody to the estrogen receptor (ER) to determine ER status from samples obtained by fine needle aspiration of primary and recurrent breast cancer tissue (cyto-ERICA). ER status was assessable on 214 of 246 smeared aspirates from breast cancer patients. In 143 (66.8%) assessable smears positive nuclear staining was observed but was completely absent in 71 (33.2%) cases. In 107 cases we were able to compare results with those obtained with the quantifiable dextrancoated charcoal (DCC) radioligand binding technique using surgically excised material. We observed qualitative agreement in 53 of 62 (85.5%) of primary specimens and 16 of 16 (100%) recurrent samples compared to the subsequent DCC result on the same sample. Aspirates obtained from new secondary deposits were also assessed and in 16 of 19 (84.2%) cases results agreed with that established previously by DCC on the primary breast tumor. In a further 6 of 10 (60%) cases the cyto-ERICA result obtained from recurrent samples qualitatively agreed with that determined by DCC on a previous recurrent lesion. A comparison of staining of aspirates was also made against frozen tissue sections stained with the monoclonal antibody (tissue-ERICA). Where comparison was made of primary tumor specimens agreement was observed in 40 of 45 (88.9%) of cases while specimens from secondary lesions agreed qualitatively in 14 of 17 (82.3%) of cases. In a small number of samples where tissue-ERICA was performed on an earlier lesion to that aspirated for cyto-ERICA an agreement of 4 of 5 (80%) was observed. This technique shows good sensitivity in demonstrating ER in aspirate specimens, should therefore permit us to determine ER status before surgery for primary breast cancer, and may also mean that surgery for recurrent disease to determine receptor status is no longer necessary.
我们开发了一种免疫细胞化学染色程序(ERICA),使用抗雌激素受体(ER)的单克隆抗体,以从通过细针穿刺原发性和复发性乳腺癌组织获得的样本中确定ER状态(细胞ERICA)。在246例乳腺癌患者的涂片抽吸物中,有214例可评估ER状态。在143例(66.8%)可评估的涂片中观察到阳性核染色,但在71例(33.2%)病例中完全没有。在107例病例中,我们能够将结果与使用手术切除材料的可量化葡聚糖包被活性炭(DCC)放射性配体结合技术获得的结果进行比较。与同一样本随后的DCC结果相比,在62例原发性标本中的53例(85.5%)和16例复发性样本中的16例(100%)中观察到定性一致。还对从新的继发性沉积物中获得的抽吸物进行了评估,在19例中的16例(84.2%)病例中,结果与先前通过DCC对原发性乳腺肿瘤确定的结果一致。在另外10例中的6例(60%)病例中,从复发性样本获得的细胞ERICA结果与先前通过DCC对复发性病变确定的结果定性一致。还对抽吸物的染色与用单克隆抗体染色的冷冻组织切片(组织ERICA)进行了比较。在对原发性肿瘤标本进行比较的情况下,在45例中的40例(88.9%)病例中观察到一致,而来自继发性病变的标本在17例中的14例(82.3%)病例中定性一致。在少数样本中,对比细胞ERICA抽吸的更早病变进行了组织ERICA,在5例中的4例(80%)中观察到一致。该技术在显示抽吸物标本中的ER方面显示出良好的敏感性,因此应该使我们能够在原发性乳腺癌手术前确定ER状态,也可能意味着不再需要为复发性疾病进行手术以确定受体状态。